PTJ
GNMX

Paul Tudor Jones’s Aevi Genomic Medicine Inc GNMX Stock Holding History

Paul Tudor Jones’s Portfolio GNMX Stock Details GNMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-80,000
Closed -$444K – 1838
2016
Q2 		$444K Buy
+80,000
New +$420K 0.01% 918

Other funds holding GNMX

BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return

Paul Tudor Jones's GNMX Position: Q3 2016 in Review

Paul Tudor Jones sold out of Aevi Genomic Medicine Inc (GNMX) in Q3 2016, closing a stake of 80,000 shares — an estimated $444K sold.

Paul Tudor Jones first reported a position in GNMX in Q2 2016 and held it in 1 quarter. The position peaked at $444K in Q2 2016. 68 funds tracked by Wall St. Rank hold GNMX as of Q3 2016.

  • Paul Tudor Jones reported no remaining Aevi Genomic Medicine Inc position as of Q3 2016 after selling out during the quarter.
  • Paul Tudor Jones sold 80,000 Aevi Genomic Medicine Inc shares in Q3 2016, an estimated $444K.
  • Paul Tudor Jones first reported a position in Aevi Genomic Medicine Inc in Q2 2016 and held it in 1 quarter.
  • Paul Tudor Jones's Aevi Genomic Medicine Inc position peaked at $444K in Q2 2016.
  • 68 funds tracked by Wall St. Rank held Aevi Genomic Medicine Inc as of Q3 2016.

Based on Tudor Investment Corp's 13F filing for Q3 2016, filed 14 Nov 2016.